A recent study has highlighted a significant finding in the field of weight loss treatments for postmenopausal women. According to the research, postmenopausal women undergoing hormone therapy exhibited significantly greater weight loss when treated with the glucagon-like peptide 1 (GLP-1) receptor agonist drug Semaglutide, compared to those not receiving hormone therapy. This preliminary yet notable study suggests that menopause itself may diminish the effectiveness of Semaglutide, a widely used anti-obesity medication.
The study, published in the journal Menopause, is the first to compare weight loss outcomes of Semaglutide in postmenopausal women with and without hormone therapy. Dr. Maria Daniela Hurtado of the Mayo Clinic, the study’s first author, noted that the data indicates hormone therapy could enhance the weight loss response to Semaglutide.
The retrospective cohort study involved 106 postmenopausal women who were overweight or obese and treated with Semaglutide for at least a year. Among these, 16 women received hormone therapy throughout the study. The results were striking: women on hormone therapy lost approximately 30% more weight than those who did not receive hormone therapy, with a mean weight loss of 16% at 12 months, similar to the weight loss observed in pivotal clinical trials of Semaglutide.
This suggests that hormone therapy might not necessarily boost Semaglutide’s typical effects but rather that the absence of hormone therapy in postmenopausal women may lead to a lower response to the drug. Women not on hormone therapy showed a 12% weight loss, indicating a diminished response.
The study also revealed that women on hormone therapy had higher weight loss percentages at various intervals (3, 6, 9, and 12 months) compared to those not on hormone therapy. These differences remained significant even after adjusting for potential confounders such as race, dyslipidemia, and depression.
Beyond weight loss, both groups showed improvements in cardiometabolic measures, including fasting glucose, A1c, and systolic blood pressure. Women on hormone therapy had additional improvements in triglycerides and total cholesterol.
Dr. Hurtado speculated that menopausal symptoms not addressed by hormone therapy might hinder weight loss efforts, affecting sleep and quality of life, and thus lifestyle changes necessary for significant weight loss.
Despite its small sample size, the study underscores the potential benefits of combining hormone therapy with Semaglutide for enhanced weight loss in postmenopausal women. However, further research with larger cohorts is necessary to confirm these findings and understand the underlying mechanisms.
As the popularity of anti-obesity drugs continues to rise, especially among menopausal women, these preliminary findings could guide future treatments and improve weight management strategies for postmenopausal women.
Source: Hurtado, M.D., et al. “More Weight Loss With Anti-Obesity Meds and Hormone Therapy.” Medscape, 2024. Available at: Medscape.
St. Petersburg, Florida
